The Main Bottleneck for Non-Metastatic Pancreatic Adenocarcinoma in Past Decades: A Population-Based Analysis

• DOI: 10.12659/msm.921515
• Publication Date: 2021-02-22T17:24:55Z
• Authors: Yuqiang Li; Wenxue Liu; Lilan Zhao; Yang Xu; Tingyu Yan; Qionghui Yang; Qian Pei; Cenap Güngör
• Keywords: Regimen

BACKGROUND Despite recent advancements in surgical techniques, chemotherapy, and radiotherapy, the 5-year survival rate of patients with pancreatic ductal adenocarcinoma (PDAC) remains an unsatisfactory ~8%. MATERIAL AND METHODS Data were extracted to identify non-metastatic diagnosed periods 1988-1996 2010-2014 Surveillance, Epidemiology, End Results (SEER) database. The statistical analyses performed log-rank test, Pearson's chi-square propensity score matching, Cox regression model. RESULTS hazard ratio (HR) surgery was reduced from 0.454 0.302 modeling, there no overlapping about 95% confidence intervals (CI) between 2 periods. HR values which new prognostic factor for resectable PDAC 2010-2014, both unresectable groups. upgraded chemotherapy regimen 0.738 0.689 all PADC patients, 0.656 0.588 PDAC. test results showed that advances significantly improved median 13 months 32 months. Radiotherapeutic chemotherapeutic extended by 12 11 months, respectively, survivals 3 radiotherapy CONCLUSIONS development has been slow, especially Although contributed PDAC, lack early diagnostic tools, lead low resection rates, remain a barrier patients.